NasdaqCM:AXGNMedical Equipment
Should Axogen’s 2026 Growth Guidance Amid Wider Losses Require Action From Axogen (AXGN) Investors?
In February 2026, Axogen, Inc. reported past full-year 2025 results, with sales rising to US$225.21 million from US$187.34 million, while net loss widened to US$15.70 million and basic loss per share from continuing operations increased to US$0.34 from US$0.23.
On the same date, Axogen issued new 2026 guidance calling for at least 18% revenue growth to about US$265.70 million and gross margins between 74% and 76%, highlighting management’s confidence in the underlying demand for its nerve...